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c-Rel Is a Target of Pentoxifylline-Mediated
Inhibition of T Lymphocyte Activation
Weihong Wang,* Winnie F. Tam,* al., 1989; Venkataraman et al., 1995). Moreover, lympho-
cyte proliferation in response to antigen receptor signalsChristopher C. W. Hughes,‡ Satyajit Rath,†
was shown to be severely inhibited in c-Rel-deficientand Ranjan Sen*
mice (Ko¨ntgen et al., 1995). Therefore, it is likely that*Rosenstiel Basic Medical Sciences Research Center
drugs affecting c-Rel and NF-AT induction will provideand Department of Biology
a means of regulating lymphocyte activation for thera-Brandeis University
peutic purposes.Waltham, Massachusetts 02254
Pentoxifylline (PF) is a vasoactive drug that is widely†National Institute of Immunology
used in the clinic as an anti-inflammatory and for theAruna Asaf Ali Marg
treatment of endotoxin shock. Although its efficacy hasNew Delhi
been attributed primarily to the inhibition of tumor necro-India
sis factor a (TNFa) production by monocytes and macro-‡Department of Molecular Biology and Biochemistry
phages (Streiter et al., 1988), it is clear that PF affectsBio Sci II
diverse cell types. For example, effects have been notedUniversity of California at Irvine
on endothelial cells (Kovach et al., 1994; Tozawa et al.,Irvine, California 92717
1995), smooth muscle cells (Bellas et al., 1995), fibrosar-
coma cell lines (Takahashi et al., 1994), neuroblastoma
cells (Yang et al., 1995), embryonic kidney cells (BiswasSummary
et al., 1993a), and lymphocytes (Biswas et al., 1993b;
Tozawa et al., 1995). The known effects on lymphocytesThe possible clinical use of the methyl xanthine deriva-
are briefly described below.tive, pentoxifylline (PF), for the treatment of T cell–
Injection of anti-CD3 antibodies in vivo has beendependent diseases is being noted with increasing
shown to induce TNFa as well as soluble TNF receptors.interest. In this paper, we studiedthe molecular conse-
PF reduced systemic TNFa and p75 TNF receptor levels,quences of PF treatment during lymphocyte activa-
suggesting that it interfered with the anti-CD3 activationtion. We found that in T cells, anti-CD3-induced c-Rel
pathways (Bemelmans et al., 1994). Furthermore, in twoexpression was blocked by PF, whereas the induction
rodent autoimmune models, PF conferred significantof other NF-kB family members was not significantly
protection against disease progression. Immunizationaffected. However, induction of NF-AT, which has the
with myelin basic protein induces experimental autoim-same signaling requirements as c-Rel induction, was
mune encephalomyelitis in rats, which is characterized
not inhibited by PF. Among genes that respond to
by loss of weight and paralysis of hind legs. These dis-
these transcription factors, IL-2 mRNA induction was
ease symptoms were almost completely abolished bysuppressed by PF, whereas IL-2Ra chain mRNAinduc-
PF administration (Rott et al., 1993). Similarly, mercuriction was not affected. These observations implicated
chloride induced arthritis in rats, which is a model of a
c-Rel as an IL-2 promoter factor, for which experimen-
Th2-type T cell disease, was also significantly decreased
tal support was obtained from transient transfection
by PF (Kiley et al., 1995). These observations not only
experiments. In contrast with the observation in T
suggest that PF may be an excellent therapeutic agent
cells, c-Rel induction was not blocked by PF in B cells. to control aberrant T cell responses, but also indicate
The greater selectivity of PF, compared with FK506, that PF may have significant immunomodulatory effects
at both the molecular and cellular levels may prove when administered for other reasons. Because little is
advantageous in manipulating T cell responses in vivo. known about the signaling pathways affected by PF, we
were prompted to initiate a systematic analysis of the
molecular consequences of PF treatment.
Introduction Our interest in PF originated from a proposed connec-
tion between NF-kB and this drug in various cell types.
Lymphocyte activation via the antigen receptors results In early studies, activation of theHIV long terminal repeat
in clonal expansion and differentiation that is critical for (LTR) in 293 embryonic kidney cells was shown to be
subsequent immune responses. Signals initiated at the diminished by nontoxic doses of PF (Biswas et al.,
plasma membrane culminate in the induction of tran- 1993a). Because induced transcriptional activity of the
scription factors that reprogram cellular gene expres- HIV LTR depends on two NF-kB-binding sites in the
sion. The induction patterns of two factors, NF-AT and enhancer region, these observations suggested that NF-
c-Rel, correlate most closely with proliferation of B and kB-dependent transcription was a target of PF. Biswas
T cells, because both proteins are induced only in re- et al. (1993b) extended their analysis to Jurkat cells,
sponse to the “complete” proliferative signal provided where a 50% decrease in NF-kB DNA binding was seen
by the combined action of phorbol ester and a calcium when the cells were stimulated with phorbol ester in
ionophore, such as ionomycin (Utz et al., 1988; Venkat- the presence of PF. More recently, Bellas et al. (1995)
araman et al., 1995). Their importance in lymphocyte reported that smooth muscle cells from bovine aorta
function is further highlighted by the observation that contained constitutive nuclear DNA–binding NF-kB,
induction of both factors is suppressed by the immuno- which was reflected in transcriptional activity of a
transfected c-myc promoter–directed reporter gene.suppressive drugs cyclosporin A and FK506 (Emmel et
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Treatment of these cells with PF decreased c-myc pro- Results
moter activity approximately 2-fold. Although NF-kB lev-
PF Inhibits NF-kB Induction in D5h3 (T) Cellsels were not directly assessed, these results were con-
To investigate the effects of PF on lymphocytes, wesistent with the interpretation that decreased c-myc
activated D5h3 T cells in the presence or absence ofpromoter activity may be due to reduction of NF-kB by
the drug and assayed the induction of transcription fac-PF. Finally, PF was shown to block the binding of human
tors by electrophoretic mobility shift assays (EMSA) andcancer cells to vascular endothelial cells (Tozawa et al.,
immunoblotting. Activation by anti-CD3 cross-linking or1995). This interaction is mediated by severalendothelial
by treatment with phorbol ester and ionomycin (datacell adhesion molecules such as ICAM-1, VCAM-1, and
not shown) strongly induced NF-kB DNA binding activityE-selectin whose expression is believed to be regulated
(Figure 1A, lane 2). We have previously shown by anti-by NF-kB proteins (Ledebur and Parks, 1995; Montgom-
body supershifts that this induced complex containsery et al., 1991; Neish et al., 1992; Schindler and Baich-
both p65 (Rel A) and c-Rel proteins (Venkataraman etwal, 1994). In this report we examined the effects of PF
al., 1996). However, it is difficult to estimate accuratelyon lymphocyte activation.
the proportion of the available nuclear DNA binding ac-In Tcells we found that c-Rel induction, which requires
tivity that is either the p50/p65 or p50/c-Rel heterodim-the dual signal of phorbol ester and ionomycin or anti-
ers, because these proteins have different affinities forCD3 treatment, was suppressed by PF. This effect was
the probe DNA and the antisera recognize the DNA-not a common feature of all Rel family members because
bound proteins with different efficiencies. In the pres-induction of NF-kB (p50/p65 heterodimer) was variably
ence of either PF (Figure 1A, lane 3) or the immuno-affected, and Rel B was not affected at all by this drug.
suppressive drug FK506 (lane 4), induction of proteins
In its effects on NF-kB family proteins, we found PF
binding to this kB DNA probe was significantly reduced.
treatment to be indistinguishable from our earlier analy-
In the experiments described above, PF and FK506 af-
sis of the immunosuppressive drug FK506 (Venkatara-
fected the induction of NF-kB proteins similarly. To ex-
man et al., 1995). However, in contrast with cyclosporin tend these observations, we examined the effect of PF
A or FK506, PF treatment did not suppress NF-AT induc- on two other well-characterized activated T cell factors.
tion or NF-AT-dependent transcription activation in Unlike NF-kB, induction of NF-AT by anti-CD3 (Figure
activated T cells. Because c-Rel induction, like NF-AT, 1B, lane 2) was not affected by PF (lane 3). As expected,
requires a calcineurin-dependent step, these observa- NF-AT induction was abolished by FK506 (Figure 1B,
tions suggest that PF affects c-Rel induction down- lane 4). Finally, neither PF nor FK506 had any effect on
stream of calcineurin. Suppression of some, but not all, the induction of AP-1 in these cells (Figure 1C). In these
inducible transcription factors was reflected in inhibition assays, treatment of cells with FK506 or PF alone (in
of interleukin-2 (IL-2) gene expression, but not interleu- the absence of cell stimulation) had no effect on the
kin-2 receptor a chain (IL-2Ra) gene induction. Interest- constitutive levels of NF-kB or NF-AT protein (data not
ingly, c-Rel induction in B cells activated by phorbol shown). These observations indicate that PF and FK506
ester and ionomycin was not blocked by PF, suggesting differentially affect inducible nuclear factors in activated
D5h3 cells; FK506 blocks c-Rel and NF-AT induction,that PF may differentially affect B and T cell responses.
Figure 1. Comparison of the Effects of PF and FK506 on Activation
of Inducible Transcription Factors in D5h3 T Cells
(A) Analysis of NF-kB DNA binding activity in nuclear extracts pre-
pared from D5h3 cells treated as indicated above the lanes. Anti-
CD3 refers to activation of cells by plate-bound anti-CD3 antibodies
for 4 hr. Drugs were added to the cells 10 min prior to cell activation.
EMSA analysis was carried out using a palindromic NF-kB-binding
site from the major histocompatibility complex class I gene pro-
moter; this sequence is referred to as the H2K probe. The arrow
indicates the position of the major inducible NF-kB complex, which
contains both p50/p65 and p50/c-Rel heterodimers. The lower, unla-
beled band contains p50/p50 homodimers.
(B) Analysis of NF-AT DNA binding activity in D5h3 nuclear extracts.
NF-AT probe is an oligonucleotide containing the NF-AT-binding
site from the murine IL-2 gene promoter. The upper arrow (labeled
NF-AT) is the major inducible complex that contains both the
NF-ATp/C cytoplasmic component and the AP-1 component. The
lower arrow (labeled NF-ATp) contains only the preexisting NF-AT
subunits without the AP-1 components.
(C) Analysis of AP-1 binding activity in D5h3 nuclear extracts. An
oligonucleotide (TCGACCCACATTAGCATGACTCATTGTTTCTGC)
containing the AP-1 site from the metallothioenine gene promoter
was used in EMSA with extracts derived from D5h3 cells treated in
various ways. The major inducible complex is labeled as AP-1 to
the right of the gel. The identity of the slower mobility complex
present equally in all lanes is presently unknown.
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Figure 2. Effect of PF and FK506 on Individ-
ual Rel Family Proteins
Analysis of c-Rel induction in D5h3 cells
treated as indicated above the lanes. Cell
treatments are summarized in the legend of
Figure 1. Nuclear (N) and cytoplasmic (C) ex-
tracts (6 mg) were fractionated by SDS–PAGE,
transferred to nitrocellulose paper, and
probed using an anti-c-Rel antiserum (A) or
an anti-Rel B antiserum (B). Arrows indicate
the positions of c-Rel and Rel B proteins.
but not induction of AP-1, whereas PF is more specific ester and a calcium ionophore (Figure 3B, first two bars),
but not after treatment with phorbol ester alone (dataand blocks only the induction of NF-kB, but not NF-AT.
Induction of specific Rel family members was further not shown), as expected based on the known properties
of NF-AT. Induced activity was efficiently suppressedmonitored by immunoblotting. c-Rel expression was in-
duced in both the cytoplasm and the nucleus by anti- by FK506; however, treatment of cells with PF resulted in
somewhat higher levels of transcription from this vectorCD3 treatment (Figure 2A, lanes 3 and 4) and was abro-
gated by both PF and FK506 (lanes 5–8). In contrast, (Figure 3B, last two bars). We reproducibly observed
increased reporter activity in cells treated with PF. Al-Rel B expression in the nucleus was not significantly
affected by activation, either in the presence or absence though the reason for this is not clear at present, one
possibility is that other DNA-binding proteins that areof the drugs (Figure 2B). Interestingly, activation of these
cells increased total cellular Rel B expression, but most suppressed by PF may compete with NF-AT for binding
to the NF-AT site, thus decreasing the effective tran-of the protein remained in the cytoplasmic fraction (Fig-
ure 2B, lanes 4, 6, and 8), suggesting that Rel B nuclear scription activation potential of NF-AT in such assays.
translocation required additional signals. We conclude
that NF-kB and c-Rel induction in activated D5h3 cells is Inhibition of IL-2 Gene Induction by PF
inhibited by PF, whereas Rel B induction is not affected. in D5h3 Cells
Thus, PF blocks the induction of a subset of Rel family Several genes are activated in response to T cell stimula-
members. tion (Ullman etal., 1990). Among these, the genes encod-
ing IL-2 and IL-2Ra play a critical role in subsequent T
cell proliferation and clonal expansion. The promotersProperties of NF-AT in PF-Treated D5h3 Cells
To investigate further the apparent lack of effect of PF of both genes are regulated by a complex array of tran-
scription factors, some of which are induced in activatedon NF-AT induction in these cells, we examined the
subunit composition and transcription activation prop- cells and others of which are constitutively expressed.
NF-AT was first identified as an inducible factor thaterties of NF-AT in PF-treated cells. In EMSA, most of
the anti-CD3 induced NF-AT in the presence or absence bound to the IL-2 promoter, and it is well established
that it is a key component required for IL-2 expressionof PF was supershifted with antisera directed against
NF-ATp (Figure 3A, compare lanes 2 and 5 with lanes 1 (Emmel et al., 1989; Flanagan et al., 1991; Utz et al.,
1988). NF-kB-binding sites have been identified in bothand 4). Both upper and lower NF-AT complexes were
significantly diminished, giving rise to two new bands the IL-2Ra (Cross et al., 1989; Leung and Nabel, 1988;
Lowenthal et al., 1989; Ruben et al., 1988) and IL-2 pro-whose positions are indicated by the arrows on the side
of the gel (Figure 3A). Consistent with the bulk of the moters. Mutation of the NF-kB site in the IL-2Ra pro-
moter abolishes inducible promoter activity, indicatingactivity being NF-ATp derived, the NF-ATC antisera did
not yield significant supershifted complexes (Figure 3A, that inducible kB-binding proteins are required for IL-
2Ra expression. The role of kB proteins in the regulationcompare lanes 3 and 6 with lanes 1 and 4). Longer
exposures of these gels revealed weak supershift bands of IL-2 is less clear. Of the two kB elements identified
in the IL-2 promoter, one has been implicated in thethat were not significantly different in the two sets of
extracts (data not shown). It is likely that the residual costimulatory response mediated via CD28 (Fraser et
al., 1991; Verweij et al., 1991) and the second in theslower migrating complex left at the position of the NF-
AT–DNA complex after anti-NF-ATp treatment repre- activation of the promoter by transactivator (tax) of type
1 human T lymphotropic virus (HTLV-1) (Ruben et al.,sents NF-ATC containing induced proteins. Comparison
of this complex in lanes 2 and 5 confirmed that the levels 1988). Neither site had been considered crucial for IL-2
induction by the T cell receptor; however, a recent studyof NF-ATC were also not affected by PF treatment.
The transcription activation properties of NF-AT were found that the distal NF-kB-binding site was important
for IL-2 induction by phytohemagglutinin (PHA) plusexamined by transient transfection assays using re-
porter plasmids containing multimerized NF-AT-binding phorbol myristate acetate (PMA) in human peripheral
blood lymphocytes (Hughes and Pober, 1996). Becausesites. Activity of the reporter in D5h3 cells was signifi-
cantly induced by treatment of the cells with phorbol of the importance of IL-2 and IL-2Ra genes in T cell
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Figure 3. Characterization of Inducible NF-
AT Activity in Cells Treated with PF
(A) Electrophoretic mobility supershift assays.
Standard in vitro binding reactions were car-
ried out using the NF-AT probe for 15 min
at room temperature, followed by addition of
normal rabbit serum (NRS), anti-NF-AT anti-
serum (NF-ATp), and anti-NF-ATC monoclonal
antibody 7A6 (NF-ATC) to the reactions and
further incubation for 1 hr on ice. Subsequent
analysis by nondenaturing electrophoresis
was as usual for EMSA. Nuclear extracts ana-
lyzed were obtained from D5h3 cells acti-
vated by plate-bound anti-CD3 antibodies for
4 hr in the absence (lanes 1–3) or presence
of PF (lanes 4–6). The two major bands seen
in lane 1 represent the complete NF-AT complex (including AP-1; upper band) and the NF-ATp/C complex alone (lower band). Positions of
supershifted bands induced by anti-NF-ATp antibodies are indicated to the right of the figure; the upper supershift band presumably represents
the complete NF-AT complex, and the lower supershift band presumably represents the partial NF-ATp/C complex.
(B) Transcription activation properties of NF-AT. A CAT reporter plasmid containing multimerized NF-AT-binding sites upstream of a truncated
c-fos gene promoter (Venkataraman et al., 1995) was transiently transfected into D5h3 cells. After 24 hr, cells were left untreated or were
treated with phorbol ester plus ionomycin alone (P1I) or in the presence of PF (labeled P1I1F) or FK506 (labeled P1I1FK). Cells were
harvested 4 hr after treatment, and CAT enzyme levels in equal amounts of whole-cell extracts were determined by ELISA. Results shown
are derived from two sets of transfections carried out in duplicate.
activation, and the possible involvement of NF-kB pro- (Figure 4C), may account for most of the difference in IL-
2Ra mRNA expression. Thus, IL-2Ra mRNA expressionteins for expression, we examined the effects of PF on
the induction of IL-2 and IL-2Ra mRNA. was not significantly affected by PF, despite the reduc-
tion of NF-kB DNA binding activity. A possible explana-Northern blot analysis of RNA isolated from D5h3 cells
showed that both IL-2Ra and IL-2 mRNAs were induced tion may be that the lower levels of NF-kB are sufficient
for IL-2Ra induction or, alternatively, that a Rel proteinwith anti-CD3 treatment (Figures 4A and 4B). When the
cells were activated in the presence of PF, we observed with low DNA binding affinity (such as a p65 homodimer)
may be the functional IL-2Ra promoter factor.a partial suppression of IL-2Ra mRNA levels (Figure 4A,
lanes 2 and 3). However, a small difference in the RNA In contrast, IL-2 mRNA induction was completely sup-
pressed by PF (Figure 4B), despite the negligible effectloading, as assessed by reprobing the filters with a glyc-
eraldehyde phosphate dehydrogenase (GAPDH) probe of this drug on NF-AT induction and transcription activa-
tion by NF-AT. These observations indicate that NF-AT,
and by extrapolation AP-1 proteins, are not sufficient
for IL-2 expression and that other inducible factors are
required to synergize with NF-AT to activate this pro-
moter. Based on the observed inhibition of Rel proteins
by PF, it is likely that NF-kB proteins may be the missing
components necessary for IL-2 gene induction.
PF Inhibits c-Rel and IL-2 Induction
in Splenic T Cells
To rule out the possibility that the observations de-
scribed above were due to the transformed nature of
D5h3 cells, we examined the effects of PF on the activa-
tion of primary, untransformed T cells. Concanavalin A
(ConA) blasts of splenic cells were activated by anti-
CD3 cross-linking in the presence or absence of PF
and FK506 and assayed by EMSA, immunoblotting and
Northern blots. NF-kB DNA binding was strongly in-
duced by anti-CD3 stimulation (Figure 5A, lanes 1 and
2). The induced nucleoprotein complex contained both
p65 and c-Rel (probably in p50/p65 and p50/c-Rel heter-
odimeric forms), as ascertained by supershift analysis
with anti-p65 as well as anti-c-Rel antibody (data not
Figure 4. Analysis of Inducible Gene Expression in D5h3 Cells shown). In contrast with the observation in D5h3 cells,
Total RNA isolated from cells (10 mg) treated as indicated was frac- NF-kB binding was not inhibited when the cells were
tionated through formaldehyde-containing agarose gels, transferred activated in the presence of PF (Figure 5A, lane 3); how-
to nitrocellulose filters, and hybridized to radioactive probes derived
ever, inclusion of FK506 reduced NF-kB inductionsignif-from IL-2Ra (A) and IL-2 (B). Expression of glyceraldehyde phos-
icantly (Figure 5A, lane 4). Effects of the drugs on NF-phate dehydrogenase (GAPDH) (C) was used as a control for RNA
loading. AT induction closely paralleled the pattern seen in D5h3
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Figure 5. Comparison of Nuclear Factor In-
duction in Splenic T Cells Activated in the
Presence of PF or FK506
(A) Analysis of NF-kB DNA binding activity in
nuclear extracts prepared from splenic T cell
ConA blasts treated as indicated above the
lanes. EMSA assays were performed using
the H2K probe and 3 mg of nuclear extracts.
The arrow indicates the position of the major
inducible NF-kB nucleoprotein complex. The
lower, unlabeled band contains p50/p50 ho-
modimers.
(B) Analysis of NF-AT induction in the same
extracts. Positions of the AP-1-containing
completeNF-AT complex andthe partial, pre-
existing NF-AT complex are indicated by the
upper and lower arrows, respectively.
(C) Effect of PF and FK506 on c-Rel induction
in splenic T cells. Nuclear (N) and cytoplasmic
(C) extracts (6 mg) from cells activated as indi-
cated were fractionated by SDS–PAGE and
transferred to nitrocellulose membranes,
which were probed with anti-c-Rel antiserum.
Position of the c-Rel protein is shown by the
arrow.
cells. Specifically, NF-AT induction (Figure 5B, lanes 1 we assayed IL-2 and IL-2Ra mRNA expression by North-
ern blotting. Both genes were strongly induced by anti-and 2) was not blocked by PF (lane 3), but was totally
abrogated by FK506 (lane 4). We conclude that PF does CD3 treatment (Figures 6A and 6B, lanes 1 and 2), and
neither drug affected IL-2Ra expression. Previously, itnot suppress either NF-kB or NF-AT induction in primary
T cells, whereas FK506 suppresses both inducible fac- has been noted that IL-2Ra expression decreased ap-
proximately 2-fold in peripheral human mononucleartors. Because most of the DNA binding NF-kB activity
observed involves the p50/p65 heterodimer, we surmise cells activated for 3 days with PHA in the presence of
PF. This small quantitative difference from our resultsthat the lack of an effect of PF on NF-kB induction
measured by EMSA indicates that p50/p65 heterodimer could be due to the extended period of stimulation used
in that study, the cell type and activation agent used,induction is unaffected by this drug. However, as shown
below, c-Rel induction by anti-CD3 was inhibited by PF. or a combination of these parameters. We conclude that
PF does not significantly affect IL-2Ra mRNA induction.We assayed specific Rel family members by immu-
noblotting. Nuclear and cytoplasmic extracts prepared However, IL-2 expression was inhibited by both PF and
FK506 (Figure 6A, lanes 3 and 4). These observationsfrom cells treated in various ways were fractionated by
SDS–polyacrylamide gel electrophoresis (SDS–PAGE), are similar to those in D5h3 cells and show that the IL-2
gene is suppressed by PF, even though this drug doestransferred to nitrocellulose membranes, and probed
with anti-c-Rel or anti–Rel B antisera. Because equal not affect either NF-kB or NF-AT induction. Based onthe
amounts of nuclear and cytoplasmic extracts wereused, suppression of c-Rel induction by PF and the possible
the relative distribution of the proteins in the nucleus is involvement of a kB element in IL-2 gene induction, we
overestimated 3- to 4-fold. In untreated T cells, c-Rel suggest that c-Rel may be a critical component of the
protein was mostly restricted to thecytoplasmic fraction IL-2 promoter.
(Figure 5C, lanes 1 and 2). Anti-CD3 treatment resulted
in increased c-Rel expression in both the nucleus and
the cytoplasm (Figure 5C, lanes 3 and 4), and the induc- c-Rel and NF-ATC Activate the IL-2 Promoter
To test whether the c-Rel gene product could activatetion was blocked by both PF and FK506 (lanes 5–8). Rel
B expression was not significantly affected by PF (data the IL-2 gene promoter, we carried out the following
transfection experiments. A reporter plasmid containingnot shown), as seen above in D5h3 cells. We conclude
that induction of certain Rel proteins such as c-Rel, but the 600 bp complete IL-2 promoter fragment (Hughes
and Pober, 1996) was cotransfected along with expres-not other Rel proteins such as NF-kB (p50/p65) or Rel
B, is blocked by PF in untransformed T cells. Thus, both sion vectors for c-Rel (Pierce et al., 1995) and NF-ATC
(Northrop et al., 1994) into 293 (nonlymphoid) cells, andPF and FK506 block c-Rel induction, but in addition
FK506 blocks NF-kB and NF-AT induction as well. promoter activity was measured using a luciferase
assay. As expected, the IL-2 reporter was inactive inTo examine the effects of PF on inducible T cell genes,
Immunity
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Figure 7. Transactivation of IL-2 Promoter by c-Rel and NF-AT
A luciferase reporter plasmid containing the wild-type human IL-2
gene promoter was cotransfected into 293 human embryonic kidney
cells together with expression vectors for c-Rel and NF-ATC, as
indicated. Cell extracts prepared 40 hr after transfection were as-
sayed for luciferase expression. Activity of the reporter plasmid is
shown normalized to that seen in the absence of cotransfected
transactivators (first bar). The results shown are derived from two
Figure 6. Expression of Inducible Genes in Splenic T Cells sets of transfections carried out in duplicate.
Total RNA isolated from the cells (10 mg) treated as indicated was
fractionated through formaldehyde-containing agarose gels and
transferred to nitrocellulose filters, which were hybridized to radio- effects on both cell types. We therefore investigated
active probes derived from IL-2 (A) and IL-2Ra (B). Equivalent RNA whether PF would have the same effect on B cells as
loading was determined by assaying GAPDH expression (C). we observed in T cells. Bal 17 B lymphoma cells were
activated with PMA and ionomycin in the presence or
absence of PF and assayed for NF-kB expression bythese cells in the absence of cotransfected transactiva-
tors (Figure 7). Neither the expression of c-Rel nor NF- EMSA and immunoblotting.
These cells contain constitutive nuclear NF-kB that isATC alone activated the IL-2 promoter significantly under
these experimental conditions (Figure 7, first three bars). detectable by EMSA in uninduced cells (Figure 8A, lane
1). Increased NF-kB was evident after stimulation withHowever, coexpression of both c-Rel and NF-ATC to-
gether resulted in synergistic transactivation of the IL-2 phorbol ester and ionomycin (Figure 8A, lane 2), which
was not suppressed in the presence of either PF orpromoter (Figure 7, fourth bar), strengthening our hy-
pothesis that c-Rel is a functional IL-2 promoter factor. FK506 (lanes 3 and 4). A lack of sensitivity to PF is
reminiscent of our observation in primary T cells; how-While carrying out these studies, we noticed that the
IL-2 promoter was also transactivated to low levels with ever, insensitivity to FK506 is clearly different from the
effects in T cells. Surprisingly, unlike T cells, PF dideither c-Rel or NF-ATC when these factors were ex-
pressed individually at higher levels, and coexpression not affect c-Rel induction in Bal 17 B cells (Figure 8B).
Indeed, in several independent experiments we notedresulted in transcriptional synergy similar to the results
shown in Figure 7 (data not shown). An additional point that the total cellular levels of c-Rel (cytoplasmic plus
nuclear) were detectably enhanced in PF-treated cellsneeds to be clarified. Because it was recently shown
that both NF-ATC and NF-ATp activated a cotransfected (for example in Figure 8B compare lanes 7 and 8 with
lanes 3 and 4). The lack of an effect of PF on c-RelIL-2 promoter to equivalent levels (Timmerman et al.,
1996), we have not repeated the studies described here induction in B cells was further confirmed in primary
splenic B cells activated with either phorbol ester pluswith NF-ATp. Our observations provide direct evidence
for functional cooperation between NF-AT and Rel pro- ionomycin or anti-immunoglobulin (data not shown).
Phorbol ester and ionomycin treatment strongly inducedteins, and implicate both factors in the regulation of IL-2
gene expression. nuclear Rel B expression (Figure 8C, lanes 2 and 4),
which was unaffected by either PF or FK506 (lanes 6
and 8). Interestingly, whereas most of the newly ex-PF Does Not Inhibit c-Rel Induction in B Cells
Activated B and T cells share many common features. pressed Rel B in activated T cells was located in the
cytoplasmic fraction (Figure 2B), most of the Rel B inFor example, both cell types require the dual signal
provided by phorbol ester and ionomycin to proliferate; activated B cellswas found in the nuclear fraction. These
observations suggest that nuclear translocation of Relboth cell types induce NF-AT and c-Rel proteins only in
response to this “complete” proliferative signal (Venka- B may be differently regulated in B and T cells. We
conclude that PF suppresses c-Rel induction in T cells,taraman et al., 1994, 1995); and immunosuppressive
drugs such as cyclosporin A and FK506 have similar but not in B cells. This observation suggests that PF
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Figure 8. Effect of PF on the Induction of Rel
Family Proteins in Bal 17 B Cells
(A) Analysis of NF-kB DNA binding. Nuclear
extracts were prepared from Bal 17 B lym-
phoma cells activated with phorbol ester and
ionomycin, in the presence or absence of
FK506 or PF, as indicated above the lanes.
The H2K probe was used for EMSA; the arrow
indicates the position of the inducible NF-
kB–DNA complex. Lane 1 shows the constitu-
tive nuclear NF-kB activity that is characteris-
tic of mature B cells.
(B and C) Expression of c-Rel and Rel B pro-
teins. Nuclear (N) or cytoplasmic (C) extracts
(6 mg) were fractionated by SDS–PAGE,
transferred to nitrocellulose membranes, and
probed with anti-c-Rel or anti-Rel B antise-
rum. Positions of c-Rel and Rel B proteins
are indicated by the arrows.
may be used to manipulate T cell activation without only c-Rel, and not NF-AT, in T cells) and at the cellular
level (c-Rel suppression occurs in T cells, but not in Baffecting B cell responses.
cells). Although the mechanistic basis for the differential
effect of PF on B and T cells is not yet understood, twoDiscussion
alternative models could account for these observa-
tions. First, c-Rel may be induced by different pathwaysIn this report we describe the effects of the drug PF on
lymphocyte activation. In T cells, three general features in B and T cells, with only the T cell pathway being
sensitive to PF. Alternatively, the induction pathway maywere noted. First, PF suppressed the induction of c-Rel
protein in response to stimulation via the T cell receptor be the same in both cell types, but B cells may have
compensatory mechanisms to circumvent the block byor its pharmacologic equivalent, phorbol ester and iono-
mycin. Its effect on the other Rel family proteins was PF. Several lines of evidence make us favor the second
model. First, the requirements for c-Rel induction aremore variable, with induction of Rel B being virtually
unaffected and the induction of NF-kB (p50/p65) de- similar in both cell types (Venkataraman et al., 1996),
suggesting a common mechanism for the induction ofpending on the cells examined. Specifically, NF-kB in-
duction was unimpaired in PF-treated splenic T cells, this gene. Second, with respect to NF-kB proteins, the
physiology of B and T cells differ in at least three ways:but significantly reduced in D5h3 hybridoma cells. It is
unlikely that the effect in D5h3 cells was solely due to B cells contain constitutively nuclear NF-kB, whereas T
cells do not; B cells rapidly translocate cytoplasmicits transformed nature, because anti-CD3-induced NF-
kB was also suppressed in the Th1 clone AE7 (W. W., c-Rel, whereas T cells do not (Venkataraman et al.,
1996); and Rel B translocation to the nucleus is moreT. L. Rothstein, and R. S., unpublished data). Second,
induction of NF-AT or AP-1 was not suppressed by PF. efficient in B cells compared with T cells (see Figures
2B and 7C). Regardless of the mechanism, these obser-We previously showed that c-Rel and NF-AT shared
indistinguishable activation characteristics, both requir- vations suggest that PF may be used to manipulate T
cell responses selectively in vivo.ing the dual signal of phorbol ester plus ionomycin, both
requiring new protein synthesis, and both proteins being Our studies have other interesting implications. We
chose to analyze IL-2 and IL-2Ra gene expression toinhibited by the immunosuppressive drug FK506. Our
present findings show that the activation of these two get an idea of the consequences of transcription factor
dysregulation by PF in activated T cells. In both trans-key regulatory proteins can be distinguished by PF. Fur-
thermore, PF must affect the c-Rel activation pathway formed and untransformed T cells, we found that IL-
2Ra expression was essentially unaffected, whereasdownstream of calcineurin, because continued NF-AT
induction suggests that calcineurin activation is unaf- IL-2 gene induction was abolished. The regulatory
sequence that governs IL-2Ra induction depends pri-fected by this drug. Third, induction of IL-2 gene, but
not the IL-2Ra gene, was blocked by PF. marily on NF-kB and serum response factor–binding
sites. We have previously shown that this inducible en-In contrast with the observations in T cells, we found
that c-Rel induction was not blocked by PF in B cells. hancer can be synergistically transactivated by serum
response factor together with either p65 or a p50/c-Thus, the greater specificity of PF compared with FK506
is reflected both at the molecular level (suppression of Rel heterodimer (Pierce et al., 1995). Because IL-2Ra
Immunity
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expression was not affected by PF whereas c-Rel induc- be true in some situations, several observations suggest
that this may not be its only mode of action.For example,tion was diminished, we propose that c-Rel is not the
major IL-2Ra kB site-binding protein in activated T cells. PF can augment differentiation of a neuroblastoma cell
line, but this activity was not mimicked by cAMP (YangContinued IL-2Ra gene induction even when NF-kB lev-
els were low (Figure 3) suggested that these low levels et al., 1995); PF did not cause a significant increase of
intracellular cAMP in human peripheral blood mononu-may be sufficient for gene induction or that strong trans-
activators with low binding affinities (such as p65 homo- clear cells, whereas the combined action of PF plus
prostanoids did elevate cAMP levels in the same cellsdimers, which would be difficult to detect in these bind-
ing assays) may be directing IL-2Ra gene expression. (Sinha et al., 1995); in 70Z pre-B cells, cAMP has been
found to activate k light chain expression (ShirakawaResults with the IL-2 gene are exactly reversed: gene
induction is suppressed independent of the levels of NF- et al., 1989), whereas we found that PF inhibited LPS-
mediated k expression (W. W., J. Durdik, S. R., and R. S.,kB. Extensive analysis of the IL-2 promoter has identified
three main categories of inducible protein-binding sites: unpublished data). Furthermore, in peripheral human T
lymphocytes, the effects of PF were not blocked byNF-AT, AP-1, and NF-kB. Because neither DNA binding
nor transcriptional activation by NF-AT and AP-1 was HA1004, an inhibitor of cAMP-dependent protein kinase
(Rao et al., 1991). Thus, the mechanism of PF actionaffected by PF, and the effects on NF-kB were variable,
the simplest interpretation of our observations is that remains unclear. It has been previously shown that
cAMP and cAMP agonists such as prostaglandin E1 andthe IL-2 promoter is a target of c-Rel. Although it is
possible that induced c-Rel activates other transcription E2 inhibit IL-2 gene induction in T cells. The molecular
mechanism of inhibition by cAMP has been investigatedfactor genes that are the functional IL-2 promoter fac-
tors, the similar time course of IL-2 and c-Rel activation in EL-4 cells and found to correlate with NF-kB (Chen
and Rothenberg, 1994) and, in particular, the Rel A com-leads us to propose that c-Rel is the functional Rel pro-
tein that activates IL-2 transcription. In support of this, ponent of NF-kB (Neuman et al., 1995). However, as
described above, we found that PF had variable effectswe found that c-Rel acted synergistically with NF-ATC
to activate the IL-2 promoter in transient transfection on Rel A, but consistently inhibited c-Rel induction in T
cells. Based on these observations, we consider it likelyassays in nonlymphoid cells. However, it is not our intent
to suggest that c-Rel and NF-AT are the only IL-2 pro- that PF action on T cells is a more complex phenomenon
than simply raising intracellular cAMP. A possible rela-moter factors or that the complete activity of the pro-
moter has been reconstituted in our experiments. In tionship of PF to calcium mobilization (Yang et al., 1995)
is particularly interesting because optimal c-Rel induc-addition, we note that the possibility that PF affects a
previously unidentified IL-2 promoter factor cannot be tion requires the dual signal of PMA plus ionomycin. PF
may therefore inhibit c-Rel induction by attenuating aunequivocally ruled out.
Families of transcription factors often share similar component of the calcium response.
DNA recognition sites; consequently it has been difficult
Experimental Proceduresto identify gene targets of specific family members. Our
proposal that the IL-2 gene may be regulated primarily
Cells and Cell Activationby c-Rel and the IL-2Ra gene by p65 provides an intrigu-
D5h3 (T) cells and Bal 17 (B) cells were grown as previously de-
ing insight into the division of labor among Rel family scribed (Venkataraman et al., 1996). Concanavalin A (ConA) blasts
proteins during T cell activation. Our results are also of splenic T cells were prepared by activating a single cell suspen-
sion of spleen cells with 2 mg/ml ConA (Calbiochem) in DMEM, 10%consistent with the activation phenotype of c-Rel-defi-
FCS, penicillin, and streptomycin for 3 days. IL-2 (10 U/ml) wascient animals (Ko¨ntgen et al., 1995). Ko¨ntgen et al.
added to the cultures every 2 days. After approximately 7 days, theshowed that B and T lymphocytes from c-Rel-deficient
cells were rested in the absence of ConA or IL-2 for 16 hr prior to
mice did not proliferate in response to signals initiated activation.
at the respective antigen receptors. In T cells, the effect For cell activation, phorbol ester (Sigma) and ionomycin (Calbio-
was primarily due to lack of IL-2 synthesis, whereas IL- chem) were used at 50 ng/ml and 2 mM, respectively. CD3 cross-
linking was carried out using plate-bound antibody. In brief, a solu-2Ra induction was not affected. Our studies with normal
tion of rabbit anti-hamster (Cappel) antibodies in PBS (100 mg/ml)mature T cells complement the analysis of c-Rel2/2 ani-
was placed in 6-well tissue culture dishes for 12 hr at 48C. Themals and argue against the possibility that the lack of
supernatant was removed, and the plates were washed three times
proliferation in c-Rel2/2 animals is due to a develop- with cold PBS to remove unbound antibody. Prior to cell activation,
mental defect caused by the lack of c-Rel. We do not anti-CD3 antibody was added to the cells at a concentration of 6
mean to imply that Rel family members never compen- mg/ml, followed by addition of cells at a density of 5 3 106 per
milliliter in complete medium. After activation, cells were scrapedsate for each other. It is possible that the endogenous
off the plates with a rubber policeman, washed three times withIL-2Ra promoter is also activated by c-Rel protein, as
PBS (48C), and used to prepare RNA or nuclear extracts.has been observed in transactivation assays. However,
For drug treatment, PF at 300 mg/ml or FK506 at 2 nM was added
in the absence of c-Rel, anotherRel protein (most proba- to the cultures 10 min prior to activation. PF concentration was
bly p65) is clearly sufficient for gene induction. That this chosen based on earlier studies that used this drug at doses of
150–900 mg/ml (Biswas et al., 1993a, 1993b; Rao et al., 1991; Streiteris not the case for IL-2 suggests a more strict require-
et al., 1988). In our own dose-response titrations, the observedment for a specific Rel family protein for IL-2 promoter
effects were significantly reduced at 150 mg/ml and unchanged atactivity, presumably to coordinate interactions with
higher (600 mg/ml) drug concentrations.other promoter factors.
Based on its chemical structure, PF is believed to Nuclear Extracts, EMSA, and Western Blots
function as a phosphodiesterase inhibitor that raises All procedures have been previously described (Venkataraman et
al., 1996). Probes for EMSA were the H2K (Mauxion et al., 1991;intracellular cyclic AMP (cAMP) levels. Although this may
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Mauxion and Sen, 1989) kB sequence and the murine NF-AT se- Cooperative inhibition of NF-kB and Tat-induced superactivation of
human immunodeficiency virus type 1 long terminal repeat. Proc.quence that we used previously (Venkataraman et al., 1994). For
immunoblotting, anti-c-Rel antibodies (SC 71; Santa Cruz Biotech- Natl. Acad. Sci. USA 90, 11044–11048.
nology) and anti-Rel B antibodies (SC 226X; Santa Cruz Biotechnol- Chen, D., and Rothenberg, E.V. (1994). Interleukin 2 transcription
ogy) were used at a 1:500 dilution. factors as molecular targets of cAMP inhibition: delayed inhibition
kinetics and combinatorial transcription roles. J. Exp. Med. 179,
Northern Blots 931–942.
Total cellular RNA was isolated using the ultraspec (Biotecx Labora-
Cross, S.L., Halden, N.F., Lenardo, M.J., and Leonard, W.J. (1989).
tories, Houston, TX) RNA isolation solution procedure, and 10 mg
Functionally distinct NF-kB binding sites in the immunoglobulin k
was fractionated through 1% agarose gels containing formaldehyde and IL-2 receptor a chain genes. Science 244, 466–469.
and transferred to nitrocellulose filters. Prehybridization was carried
Emmel, E.A., Verweij, C.L., Durand, D.B., Higgins, K.M., Lacy, E., andout for 30 min in 50% deionized formamide, 53 SSPE, 53 Denhardt’s
Crabtree, G.R. (1989). Cyclosporin A specifically inhibits function ofsolution, 0.5% SDS, 100 mg/ml salmon sperm DNA at 428C. Probes
nuclear proteins involved in T cell activation. Science 246, 1617–(described below) were radiolabeled by random priming and used
1620.at a concentration of 2 3 106 cpm per milliliter of hybridization buffer.
Flanagan, W.M., Corthesy, B., Bram, R.J., and Crabtree, G.R. (1991).
Nuclear association of a T-cell transcription factor blocked by FK-Probes
506 and cyclosporin A. Nature 352, 803–807.Probes were as follows: IL-2, a 900 bp PstI fragment was isolated
from pIL-2-sense (gift of Dr. B. Huber, Tufts University School of Fraser, J.D., Irving, B.A., Crabtree, G.R., and Weiss, A. (1991). Regu-
Medicine, Boston, MA); IL-2Ra, 1 kb EcoRI–XbaI fragment con- lation of interleukin-2 gene enhancer activity by the T cell accessory
taining the murine IL-2Ra cDNA was isolated from pGEM-1-R8- molecule CD28. Science 251, 313–316.
1000Exb (Miller et al., 1985; gift of Dr. A. Rao, Dana-Farber Cancer
Hughes, C.C., and Pober, J.S. (1996). Transcriptional regulation of
Institute, Boston, MA); GAPDH, a 750 PstI–KpnI fragment was iso-
the interleukin-2 gene in normal human peripheral blood T cells:
lated from pBSKII1 rat GAPDH clone (gift of Dr. M. Baron, Harvard
convergence of costimulatory signals and differences from trans-
University, Cambridge, MA).
formed T cells. J. Biol. Chem. 271, 5369–5377.
Kiley, P.D., Gillespie, K.M., and Oliveira, D.B. (1995). OxpentifyllineTransient Transfections
inhibits tumor necrosis factor-a mRNA transcription and protectsD5h3 (T hybridoma) cells (5 3 106) were transfected with 10 mg of
against arthritis in mercuric chloride-treated brown Norway rats.reporter plasmids using DEAE–dextran (Nelsen et al., 1990). At 24
Eur. J. Immunol. 25, 2899–2906.hr posttransfection, cells were treated with phorbol ester, iono-
mycin, and PF as indicated for an additional 4 hr. Cells were har- Ko¨ntgen, F., Grumont, R.J., Strasser, A., Metcalf, D., Li, R., Tarlintou,
vested and 50 mg of whole-cell extracts was assayed for CAT en- D., and Gerondakis, S. (1995). Mice lacking the c-rel proto-oncogene
zyme by ELISA (Boehringer Mannheim). exhibit defects in lymphocyte proliferation, humoral immunity, and
293 (human embryonic kidney) cells were transfected using cal- interleukin-2 expression. Genes Dev. 9, 1965–1977.
cium phosphate with a wild-type IL-2 promoter luciferase reporter Kovach, N.L., Lindgren, C.G., Fefer, A., Thompson, J.A., Yednock,
plasmid (Hughes and Pober, 1996) in the presence or absence of T., and Harlan, J.M. (1994). Pentoxifylline inhibits integrin-mediated
2 mg of expression vectors for transactivators c-Rel and NF-ATC adherence of interleukin-2-activated human peripheral blood lym-
(Northrop et al., 1994; Venkataraman et al., 1995). When no or only phocytes to human umbilical vein endothelial cells, matrix compo-
one transactivator was present, the total DNA was held constant at nents, and culture tumor cells. Blood 84, 2234–2242.
6 mg using an expression vector containing no insert. Cells were
Ledebur, H.C., and Parks, T.P. (1995). Transcriptional regulation oflysed in lysis buffer 48 hr after transfection (Analytic Luminescence
the intercellular adhesion molecule-1 gene by inflammatory cyto-Laboratory, Ann Arbor, MI), and 20 mg of extract was used for the
kines in human endothelial cells: essential roles of a variant NF-kBluciferase assay. Luciferase activity was normalized to that seen in
site and p65 homodimers. J. Biol. Chem. 270, 933–943.the absence of cotransfected transactivator plasmids.
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